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Sum 
Ris-ras 
Cream 
1 
Cream 
2 
Cream 
3 
Cream 
4 
Cream 
5 
Cream 
6 
Cream 
7 
mean 8.47 9.19 8. 37 8.43 7.37 7.94 7.39 
min 6.85 6 6.5 6 6.12 6.6 6 
max 11.25 13.5 10.25 10.5 9.33 12.5 10 
sd 1.44 2.51 1.36 1.44 0.97 1.88 2.69 
 
Cosmeti
c 
properti
es 
Cream
1 
Crea
m 2 
Cream 
3 
Cream 
4 
Cream 
5 
Cream 
6 
Crea
m 7 
Extensio
n 
8.54 9.37 8 8.6 8.09 9.22 6.45 
relief 8.45 7 7.3 7.2 7.54 8.66 5.45 
perman
ence 
8.18 7 7.2 8.9 7.54 8.66 5.45 
freshnes
s 
8 7.62 6.3 6.6 7.36 7.11 5.81 
smell 8.18 7.37 7.6 6.7 6.81 7.77 5.63 
absorpti
on 
8.36 9 7.9 5.8 6.81 9.44 6.18 
waste 8.18 5.5 5.4 7.7 6.63 9.66 4.82 
overall 
satisfact
ion 
8.1 7.87 8.66 7.5 8.36 9.33 6.18 
PVP 200ml/
24€ 
 0,095 
€ ml 
50ml/
25€  
0,48 € 
ml 
400ml/
20€  
0,05 € 
ml 
250ml/
15€  
0,06 € 
ml 
250ml/
26€  
0,104 € 
ml 
500ml/
29€  
0,058€ 
ml 
75ml/
30€  
0,4€ 
ml 
 
Conclusions: Our results don't show significant objective 
differences on acute radiodermitis; but significant 
differences were seen on the patient's lotion approval and 
cost. We believe that an expanded study with more patients 
is of interest.  
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Purpose/Objective:The purpose of this retrospective study 
was to evaluate the palliative role of radiotherapy (RT) in 
terms of clinical benefit in locally advanced or metastatic 
rectal cancer patients (pts).  
Materials and Methods: All pts with locally advanced disease 
and pelvic recurrence unfit for surgery or with metastatic 
disease, independently of previous treatments, were 
enrolled. The scheduled RT was 25 Gy in 5 fractions delivered 
in 5-7 days. The clinical target volume included the primary 
tumor, correspondent mesorectum, clinically involved loco-
regional lymph-nodes plus a 2 cm of margin or in case of 
pelvic recurrence the site of disease plus a 2 cm of margin. 
Three-dimensional conformal RT was used. The benefit of 
treatment was evaluated only relying on medical 
examination; in particular pain relief was assessed both by 
VAS scale and consumption of analgesic drugs. Symptom 
palliation was defined at one month after the end of RT. 
Each pt was followed every three-four months or otherwise 
the clinical information was collected by phone. A minimum 
of one month follow-up was requested for the analysis. 
Toxicity was classified according to the RTOG/EORTC scale. 
Results: From May 2007 to October 2014, 28 pts were 
treated. Pts characteristics are as follows. Gender: male 14 
(50%); female 14 (50%); stage: II 1 (3,5%), III 10 (36%), IV 8 ( 
29%), local recurrence 9 (32%); median age 79.5 years (range 
49-90); median KPS 70% (range 50-100). Initial presenting 
symptoms were: bleeding in 24 (85,7%); pain in 9 (32,1%); 
rectal tenesmus in 7 (25%); patter change in 7 (25%); 
mucorrea in 5 pts (17,8%). Among the 28 pts, 7 (25 %) 
underwent chemotherapy as first treatment and received RT 
due to local progression of the disease; of these five (71,4%) 
had stage IV and two (28,6%) local recurrence. All pts 
completed the scheduled treatment. Overall, twenty-four 
(85,6%) pts responded to RT; in particular 18 (64,2%) 
experienced complete remission, 6 (21,4%) significant 
improvement, while 4 (14,4%) no change of symptoms. 
Regarding response obtained according to type of symptom, 
bleeding disappeared in 83% of pts, pain relief was obtained 
in 89% and rectal tenesmus in 92,8%. Symptoms relapse 
occurred in only 4 (14%) pts, as bleeding (3 cases) and rectal 
tenesmus (1 case). RT was well tolerated; only one pt 
developed acute urinary retention that required temporary 
application of bladder catheter. Two pts with wide vaginal 
involvement, as a consequence of response to treatment, 
experienced a recto-vaginal fistula. Median time to symptom 
relapse was 8 months (range 2-71). Median survival after RT 
was 8.5 months (range 2-71). Twenty-two (77%) pts died, but 
only 5 (15%) for local disease progression.  
Conclusions: Our results suggest that short-course RT can be 
feasible and effective in this subset of rectal cancer pts, both 
in terms of symptoms relief rate and duration of clinical 
benefit. 
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Purpose/Objective: Malignant spinal cord compression 
(MSCC) is an oncology emergency that requires prompt 
diagnosis and management to minimise morbidity and 
improve patient outcome. In order to minimise delay in 
diagnosis and initiation of treatment a malignant spinal cord 
pathway has been devised and implemented throughout the 
cancer network. This prospective audit aimed to identify the 
proportion of patients meeting the recommendations of the 
pathway-MRI(or CT if contraindicated) within 24 hours of 
presentation with suspected MSCC; treatment decision 
(surgery or RT) within 24hours of diagnosis of MSCC; in 
patients in whom RT is recommended treatment to 
commence within 24hours of MRI. 
Materials and Methods: MSCC cases were identified from 
requests for whole spine MRI in patients with suspected 
